#18icml search results
Together we lead, we learn, we lift each other up. Thank you to all who joined our WiL gathering at #18ICML — an inspiring evening filled with connection, purpose, and power. Let’s keep building this global community, one voice at a time. 🌍 #womeninhematology #ICML2025
Is Acala-benda-R the new soc for transplant ineligible high risk patients in mantle cell lymphoma? Thoughts? #18ICML #ICML2025
#18ICML LBA: DLBclass stratification of POLARIX - Cluster 5 DLBCL had superior PFS with pola-R-CHP vs R-CHOP (including in MV model) - C5: ABC-type, +BCL2, CD79Bmut, MYD88mut, extranodal #lymsm
Impressive early data for VIPOR in mantle cell lymphoma, including in patients with TP53-aberrant disease #18ICML #lymsm
David Scott’s @BCCancer algorithm for treatment of newly-diagnosed DLBCL based on recent Canadian recommendation for polatuzumab reimbursement for ABC-subtype DLBCL #lymsm #18ICML @AshAlizadeh
Data from the Shipp lab @DanaFarber support that the benefit of polatuzumab in 1L DLBCL is isolated to a subgroup of patients with C5 DLBCL, a subset of the ABC group #18ICML #lymsm
UBC study of DA-R-EPOCH in DHL (implemented provincewide in 2015). Superior TTP & OS with EPOCH vs RCHOP era. No difference in survival based on MYC Ig partner. OS worse with EPOCH if DZsig+. #18ICML #lymsm
Impressive data in the challenging-to-treat Richter’s transformation population with Ven+R-CHOP with 50% PFS at 15 months #18ICML #lymsm
Dr Teresa Calimeri presents an @TheEBMT registry study in PCNSL. No difference in PFS in CR vs. PR pre-ASCT found (also seen in IELSG32). Interestingly, 2y PFS was 50% in 49 patients in PD pre-ASCT. Do we need more sensitive response assessment methods? #18icml
Best slide of #18ICML #ICML2025! COO/Dark signature #DLBCL. Magisterial Gianni Bonadonna lecture by Dr. David Scott from BCC. It was like a “Great Gig in the sky” realizing how far we have achieved in this #lymphoma. Only a matter of “Time” to be out of the eclipse “….
Tafa-R-len improved PFS and TTNT in R/R FL without loss of cd19 expression at relapse (important for those who have cart therapy as a treatment possibility in 3L and beyond) #18ICML #ICML2025
🚨 POTENTIAL NEW SOC IN R/R FOLLICULAR #LYMPHOMA!! PFS superiority of Tafasitamab-R2 against Placebo-R2 (inMIND phase 3 trial) 📈 Besides, almost all relapses were CD19+ (thus, subsequent CAR-T access is not compromised) Presented by Dr L Sehn at #ICML2025 #18ICML @icmlugano
Appealing data for combo of loncastuximab + glofitamab in RR DLBCL 7.3% effusion TEAEs leading to lonca discontinuation #lymsm #18ICML
Our team are back from #18ICML in Lugano, buzzing with new connections and insights. We can’t wait to share more soon! Plus, don’t miss our FREE webinar on July 9th where we discuss how close we really are to a cure in #follicularlymphoma Sign up here: us02web.zoom.us/webinar/regist…
Beyond proud of our @MSK_RadOnc hematology research team! Exciting research at the forefront of all aspects of #18ICML!! Hopefully the Lago view makes up for all the hard work 😉 @MSKCancerCenter
Our diverse pipeline and portfolio are driven by a deep understanding of causal human biology and the complexities of cancer. We look forward to presenting data at this year’s #ASCO25, #EHA2025 and #18ICML. Learn more: bit.ly/43vXVle
Double trouble! Congrats to @RoshalPatel on his important work showing that bridging RT prior to CAR T cells is safe and probably needs greater personalization by tumor genetics. Great work! @MSK_RadOnc @MSKCancerCenter #18ICML
Impressive early data for VIPOR in mantle cell lymphoma, including in patients with TP53-aberrant disease #18ICML #lymsm
Is Acala-benda-R the new soc for transplant ineligible high risk patients in mantle cell lymphoma? Thoughts? #18ICML #ICML2025
#18ICML LBA: DLBclass stratification of POLARIX - Cluster 5 DLBCL had superior PFS with pola-R-CHP vs R-CHOP (including in MV model) - C5: ABC-type, +BCL2, CD79Bmut, MYD88mut, extranodal #lymsm
David Scott’s @BCCancer algorithm for treatment of newly-diagnosed DLBCL based on recent Canadian recommendation for polatuzumab reimbursement for ABC-subtype DLBCL #lymsm #18ICML @AshAlizadeh
Data from the Shipp lab @DanaFarber support that the benefit of polatuzumab in 1L DLBCL is isolated to a subgroup of patients with C5 DLBCL, a subset of the ABC group #18ICML #lymsm
Thanks @JudithTrotman1 for opening this great session offering avenues that will empower patients and make their voice louder, including in clinical trials. Yes, HRQoL should be a co-primary endpoint in the majority of heme trials! Cc @icmlconf @knowyournodes @majorajay #18ICML
Together we lead, we learn, we lift each other up. Thank you to all who joined our WiL gathering at #18ICML — an inspiring evening filled with connection, purpose, and power. Let’s keep building this global community, one voice at a time. 🌍 #womeninhematology #ICML2025
#ICOnic representation @HematICO_Hosp @ICO_oncologia at #ICML2025 #18ICML @WomenInLymphoma @AnnaSureda5 @Evadodo23 #AnaOliveira
🚨 POTENTIAL NEW SOC IN R/R FOLLICULAR #LYMPHOMA!! PFS superiority of Tafasitamab-R2 against Placebo-R2 (inMIND phase 3 trial) 📈 Besides, almost all relapses were CD19+ (thus, subsequent CAR-T access is not compromised) Presented by Dr L Sehn at #ICML2025 #18ICML @icmlugano
With Polargo, starglo, and sumno showing survival advantage (os and/or pfs) over R-gemox, are we still confortable with r-gemox as control arm for ongoing R/R DLBCL trials? #18icml #icml2025
Come and see first cut of #goldilox what glofit and pirto can do together for bad mantle cell lymphoma. #18icml #lymsm #allg
Impressive data in the challenging-to-treat Richter’s transformation population with Ven+R-CHOP with 50% PFS at 15 months #18ICML #lymsm
Appealing data for combo of loncastuximab + glofitamab in RR DLBCL 7.3% effusion TEAEs leading to lonca discontinuation #lymsm #18ICML
Huge interest in older patients 👵👴 with #Hodgkin #Lymphoma at #18ICML #icml2025. Don’t miss posters P365 by @ABarrettHaem, P366 by Peiqi Zhao, and P367 by @Evadodo23. There is so much room for improvement in this area. Let’s work together in collaborative projects 🇪🇸🇬🇧🇨🇳 #lymsm
Lotis-7: loncaT with glofit RR DLBCL Small nos and early data but VERY high response rates with well over 80% CMR rate. One to watch. #18ICML #ICML25 #lymsm
Bispecifics in the frontline? In EPCORE NHL-5, Epcoritamab + pola-R-CHP in 1L DLBCL: – ORR 100%, CRR 97% – 81% MRD– by C3D1 (ctDNA!) Durable, deep responses. No ICANS. All CRS low grade. #ICML2025 #18ICML #lymsm
Something went wrong.
Something went wrong.
United States Trends
- 1. #FanCashDropPromotion 1,936 posts
- 2. Summer Walker 25.6K posts
- 3. Good Friday 58.6K posts
- 4. Wale 38.1K posts
- 5. #FridayVibes 5,042 posts
- 6. #NXXT_Earnings N/A
- 7. #FinallyOverIt 8,533 posts
- 8. #FridayFeeling 2,411 posts
- 9. Happy Friyay 1,621 posts
- 10. Saylor 44.2K posts
- 11. Go Girl 25.6K posts
- 12. SINGSA LATAI EP3 60.7K posts
- 13. Doug McMillon N/A
- 14. Bubba 11.5K posts
- 15. Meek 6,571 posts
- 16. Bill Clinton 61.5K posts
- 17. Robbed You 5,296 posts
- 18. $BTC 122K posts
- 19. Thomas Crooks 40.6K posts
- 20. Red Friday 3,868 posts